{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:02:59Z","timestamp":1791424979285,"version":"4.3.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40262-024-01363-6","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T09:02:57Z","timestamp":1711443777000},"page":"657-668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Predictions of Bedaquiline Central Nervous System Exposure in Patients with Tuberculosis Meningitis Using Physiologically based Pharmacokinetic Modeling"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-6436","authenticated-orcid":false,"given":"Krina","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Balazki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet H.","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. G. Coen","family":"van Hasselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"1363_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/wellcomeopenres.15573.1","volume":"4","author":"JA Seddon","year":"2019","unstructured":"Seddon JA, Wilkinson R, van Crevel R, et al. Knowledge gaps and research priorities in tuberculous meningitis. Wellcome Open Res. 2019;4:1\u201318. https:\/\/doi.org\/10.12688\/wellcomeopenres.15573.1.","journal-title":"Wellcome Open Res."},{"issue":"7","key":"1363_CR2","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1007\/s00415-022-11052-8","volume":"269","author":"A Navarro-Flores","year":"2022","unstructured":"Navarro-Flores A, Fernandez-Chinguel JE, Pacheco-Barrios N, Soriano-Moreno DR, Pacheco-Barrios K. Global morbidity and mortality of central nervous system tuberculosis: a systematic review and meta-analysis. J Neurol. 2022;269(7):3482\u201394. https:\/\/doi.org\/10.1007\/s00415-022-11052-8.","journal-title":"J Neurol"},{"issue":"7","key":"1363_CR3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/cid\/ciw566","volume":"63","author":"P Nahid","year":"2016","unstructured":"Nahid P, Dorman SE, Alipanah N, et al. Executive Summary: Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):853\u201367. https:\/\/doi.org\/10.1093\/cid\/ciw566.","journal-title":"Clin Infect Dis"},{"key":"1363_CR4","doi-asserted-by":"publisher","DOI":"10.19080\/OAJNN.2018.08.555734","author":"R Ramachandran","year":"2018","unstructured":"Ramachandran R, Muniyandi M. Towards improved treatment outcomes for tuberculosis meningitis\u2014rethinking the regimen. Open Access J Neurol Neurosurg. 2018. https:\/\/doi.org\/10.19080\/OAJNN.2018.08.555734.","journal-title":"Open Access J Neurol Neurosurg"},{"issue":"1","key":"1363_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","volume":"13","author":"R Ruslami","year":"2013","unstructured":"Ruslami R, Ganiem AR, Dian S, Apriani L, Achmad TH, van der Ven AJ, Borm G, Aarnoutse RE, van Crevel R. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 2013;13(1):27\u201335. https:\/\/doi.org\/10.1016\/S1473-3099(12)70264-5.","journal-title":"Lancet Infect Dis"},{"issue":"13","key":"1363_CR6","doi-asserted-by":"publisher","first-page":"1048653","DOI":"10.3389\/fphar.2022.1048653","volume":"12","author":"NF Maranchick","year":"2022","unstructured":"Maranchick NF, Alshaer MH, Smith AGC, Avaliani T, Gujabidze M, Bakuradze T, Sabanadze S, Avaliani Z, Kipiani M, Peloquin CA, Kempker RR. Cerebrospinal fluid concentrations of fluoroquinolones and carbapenems in tuberculosis meningitis. Front Pharmacol. 2022;12(13):1048653. https:\/\/doi.org\/10.3389\/fphar.2022.1048653.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1363_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/cid\/cix230","volume":"65","author":"AD Heemskerk","year":"2017","unstructured":"Heemskerk AD, Nguyen MTH, Dang HTM, Vinh Nguyen CV, Nguyen LH, Do TDA, Nguyen TTT, Wolbers M, Day J, Le TTP, Nguyen BD, Caws M, Thwaites GE. Clinical outcomes of patients with drug-resistant tuberculous meningitis treated with an intensified antituberculosis regimen. Clin Infect Dis. 2017;65(1):20\u20138. https:\/\/doi.org\/10.1093\/cid\/cix230.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1363_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0270201","volume":"17","author":"EE Evans","year":"2022","unstructured":"Evans EE, Avaliani T, Gujabidze M, et al. Long term outcomes of patients with tuberculous meningitis: the impact of drug resistance. PLoS\u00a0One. 2022;17(6): e0270201. https:\/\/doi.org\/10.1371\/journal.pone.0270201.","journal-title":"PLoS\u00a0One"},{"key":"1363_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jgar.2021.02.017","volume":"25","author":"S Khoshnood","year":"2021","unstructured":"Khoshnood S, Goudarzi M, Taki E, et al. Bedaquiline: current status and future perspectives. J Glob Antimicrob Res. 2021;25:48\u201359. https:\/\/doi.org\/10.1016\/j.jgar.2021.02.017.","journal-title":"J Glob Antimicrob Res."},{"issue":"5707","key":"1363_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/science.1106753","volume":"307","author":"K Andries","year":"2005","unstructured":"Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307(5707):223\u20137. https:\/\/doi.org\/10.1126\/science.1106753.","journal-title":"Science"},{"key":"1363_CR11","unstructured":"World Health Organization. Consolidated operational guidelines on handbook tuberculosis. 2020. https:\/\/www.who.int\/publications\/i\/item\/9789240063129."},{"issue":"4","key":"1363_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/cid\/civ921","volume":"62","author":"OW Akkerman","year":"2015","unstructured":"Akkerman OW, Odish OFF, Bolhuis MS, et al. Pharmacokinetics of bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculous meningitis. Clin Infect Dis. 2015;62(4):523\u20134. https:\/\/doi.org\/10.1093\/cid\/civ921.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1363_CR13","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/jac\/dkac067","volume":"77","author":"CM Upton","year":"2022","unstructured":"Upton CM, Steele CI, Maartens G, Diacon AH, Wiesner L, Dooley KE. Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB). J Antimicrob Chemother. 2022;77(6):1720\u20134. https:\/\/doi.org\/10.1093\/jac\/dkac067.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"1363_CR14","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1021\/acsinfecdis.9b00207","volume":"5","author":"AA Ordonez","year":"2019","unstructured":"Ordonez AA, Carroll LS, Abhishek S, et al. Radiosynthesis and PET bioimaging of 76Br-bedaquiline in a murine model of tuberculosis. ACS Infect Dis. 2019;5(12):1996\u20132002. https:\/\/doi.org\/10.1021\/acsinfecdis.9b00207.","journal-title":"ACS Infect Dis."},{"issue":"22","key":"1363_CR15","doi-asserted-by":"publisher","first-page":"11902","DOI":"10.1039\/c8ra00984h","volume":"8","author":"A Pamreddy","year":"2018","unstructured":"Pamreddy A, Baijnath S, Naicker T, et al. Bedaquiline has potential for targeting tuberculosis reservoirs in the central nervous system. RSC Adv. 2018;8(22):11902\u20137. https:\/\/doi.org\/10.1039\/c8ra00984h.","journal-title":"RSC Adv"},{"issue":"1","key":"1363_CR16","doi-asserted-by":"publisher","first-page":"7974","DOI":"10.1038\/s41467-022-35730-3","volume":"13","author":"F Mota","year":"2022","unstructured":"Mota F, Ruiz-Bedoya CA, Tucker EW, et al. Dynamic 18F-Pretomanid PET imaging in animal models of TB meningitis and human studies. Nat Commun. 2022;13(1):7974. https:\/\/doi.org\/10.1038\/s41467-022-35730-3.","journal-title":"Nat Commun"},{"issue":"1","key":"1363_CR17","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1128\/AAC.01691-15","volume":"60","author":"R Tasneen","year":"2016","unstructured":"Tasneen R, Betoudji F, Tyagi S, et al. Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2016;60(1):270\u20137. https:\/\/doi.org\/10.1128\/AAC.01691-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"1363_CR18","unstructured":"Food and Drug Administration (FDA). FDA Briefing Document Pretomanid Tablet, 200 mg Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC). Published online 2019. https:\/\/www.fda.gov\/media\/127592\/download."},{"issue":"8","key":"1363_CR19","doi-asserted-by":"publisher","first-page":"632","DOI":"10.5588\/ijtld.21.0159","volume":"25","author":"AGC Smith","year":"2021","unstructured":"Smith AGC, Gujabidze M, Avaliani T, et al. Clinical outcomes among patients with tuberculous meningitis receiving intensified treatment regimens. Int J Tuberc Lung Dis. 2021;25(8):632\u20139. https:\/\/doi.org\/10.5588\/ijtld.21.0159.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"1363_CR20","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1164\/rccm.201410-1801OC","volume":"191","author":"AH Diacon","year":"2015","unstructured":"Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Critical Care Med. 2015;191(8):943\u201353. https:\/\/doi.org\/10.1164\/rccm.201410-1801OC.","journal-title":"Am J Respir Critical Care Med."},{"issue":"10","key":"1363_CR21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/psp4.12134","volume":"5","author":"L Kuepfer","year":"2016","unstructured":"Kuepfer L, Niederalt C, Wendl T, et al. Applied concepts in PBPK modeling: how to build a PBPK\/PD model. CPT Pharmacometrics Syst Pharmacol. 2016;5(10):516\u201331. https:\/\/doi.org\/10.1002\/psp4.12134.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"1363_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-007-9053-5","volume":"34","author":"S Willmann","year":"2007","unstructured":"Willmann S, H\u00f6hn K, Edginton A, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007;34(3):401\u201331. https:\/\/doi.org\/10.1007\/s10928-007-9053-5.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"1363_CR23","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1023\/B:PHAM.0000003373.72652.c0","volume":"20","author":"S Willmann","year":"2003","unstructured":"Willmann S, Schmitt W, Keldenich J, Dressman JB. A physiologic model for simulating gastrointestinal flow and drug absorption in rats. Pharm Res. 2003;20(11):1766\u201371. https:\/\/doi.org\/10.1023\/B:PHAM.0000003373.72652.c0.","journal-title":"Pharm Res"},{"issue":"10","key":"1363_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/psp4.12034","volume":"4","author":"L Gaohua","year":"2015","unstructured":"Gaohua L, Wedagedera J, Small BG, et al. Development of a multicompartment permeability-limited lung PBPK model and its application in predicting pulmonary pharmacokinetics of antituberculosis drugs. CPT Pharmacometrics Syst Pharmacol. 2015;4(10):605\u201313. https:\/\/doi.org\/10.1002\/psp4.12034.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"9","key":"1363_CR25","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1093\/jac\/dku171","volume":"69","author":"RPG van Heeswijk","year":"2014","unstructured":"van Heeswijk RPG, Dannemann B, Hoetelmans RMW. Bedaquiline: a review of human pharmacokinetics and drug\u2013drug interactions. J Antimicrob Chemother. 2014;69(9):2310\u20138. https:\/\/doi.org\/10.1093\/jac\/dku171.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"1363_CR26","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/psp4.12147","volume":"5","author":"EM Svensson","year":"2016","unstructured":"Svensson EM, Dosne AG, Karlsson MO. Population pharmacokinetics of bedaquiline and metabolite m2 in patients with drug-resistant tuberculosis: the effect of time-varying weight and albumin. CPT Pharmacometrics Syst Pharmacol. 2016;5(12):682\u201391. https:\/\/doi.org\/10.1002\/psp4.12147.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"9","key":"1363_CR27","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1128\/AAC.01418-13","volume":"58","author":"SC McLeay","year":"2014","unstructured":"McLeay SC, Vis P, Van Heeswijk RPG, Green B. Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug. Antimicrob Agents Chemother. 2014;58(9):5315\u201324. https:\/\/doi.org\/10.1128\/AAC.01418-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1363_CR28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s40262-023-01217-7","volume":"62","author":"K Mehta","year":"2023","unstructured":"Mehta K, Guo T, van der Graaf PH, van Hasselt JGC. Predictions of bedaquiline and pretomanid target attainment in lung lesions of tuberculosis patients using translational minimal physiologically based pharmacokinetic modeling. Clin Pharmacokinet. 2023;62(3):519\u201332. https:\/\/doi.org\/10.1007\/s40262-023-01217-7.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1363_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.tiv.2007.09.010","volume":"22","author":"W Schmitt","year":"2008","unstructured":"Schmitt W. General approach for the calculation of tissue to plasma partition coefficients. Toxicol In Vitro. 2008;22(2):457\u201367. https:\/\/doi.org\/10.1016\/j.tiv.2007.09.010.","journal-title":"Toxicol In Vitro"},{"issue":"3","key":"1363_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/psp4.12904","volume":"12","author":"H Cordes","year":"2023","unstructured":"Cordes H, Rapp H. Gene expression databases for physiologically based pharmacokinetic modeling of humans and animal species. CPT Pharmacometrics Syst Pharmacol. 2023;12(3):311\u20139. https:\/\/doi.org\/10.1002\/psp4.12904.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"1363_CR31","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1124\/dmd.113.056119","volume":"42","author":"K Liu","year":"2014","unstructured":"Liu K, Li F, Lu J, et al. Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. 2014;42(5):863\u20136. https:\/\/doi.org\/10.1124\/dmd.113.056119.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"1363_CR32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11095-016-2065-3","volume":"34","author":"Y Yamamoto","year":"2017","unstructured":"Yamamoto Y, V\u00e4litalo PA, van den Berg DJ, et al. A generic multi-compartmental CNS distribution model structure for 9 drugs allows prediction of human brain target site concentrations. Pharm Res. 2017;34(2):333\u201351. https:\/\/doi.org\/10.1007\/s11095-016-2065-3.","journal-title":"Pharm Res"},{"issue":"3","key":"1363_CR33","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.dmpk.2016.03.005","volume":"31","author":"L Gaohua","year":"2016","unstructured":"Gaohua L, Neuhoff S, Johnson TN, Rostami-Hodjegan A, Jamei M. Development of a permeability-limited model of the human brain and cerebrospinal fluid (CSF) to integrate known physiological and biological knowledge: estimating time varying CSF drug concentrations and their variability using in vitro data. Drug Metab Pharmacokinet. 2016;31(3):224\u201333. https:\/\/doi.org\/10.1016\/j.dmpk.2016.03.005.","journal-title":"Drug Metab Pharmacokinet."},{"issue":"5","key":"1363_CR34","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10928-021-09768-7","volume":"48","author":"MAA Saleh","year":"2021","unstructured":"Saleh MAA, Loo CF, Elassaiss-Schaap J, De Lange ECM. Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations. J Pharmacokinet Pharmacodyn. 2021;48(5):725\u201341. https:\/\/doi.org\/10.1007\/s10928-021-09768-7.","journal-title":"J Pharmacokinet Pharmacodyn."},{"issue":"6","key":"1363_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1007117","volume":"15","author":"LFM Verscheijden","year":"2019","unstructured":"Verscheijden LFM, Koenderink JB, de Wildt SN, Russel FGM. Development of a physiologically-based pharmacokinetic pediatric brain model for prediction of cerebrospinal fluid drug concentrations and the influence of meningitis. PLoS Comput Biol. 2019;15(6): e1007117. https:\/\/doi.org\/10.1371\/journal.pcbi.1007117.","journal-title":"PLoS Comput Biol"},{"issue":"10","key":"1363_CR36","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1124\/DMD.120.090498","volume":"48","author":"K Utsey","year":"2020","unstructured":"Utsey K, Gastonguay MS, Russell S, Freling R, Riggs MM, Elmokadem A. Quantification of the impact of partition coefficient prediction methods on physiologically based pharmacokinetic model output using a standardized tissue composition. Drug Metab Dispos. 2020;48(10):903\u201316. https:\/\/doi.org\/10.1124\/DMD.120.090498.","journal-title":"Drug Metab Dispos."},{"issue":"7","key":"1363_CR37","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S0022-2275(20)31605-9","volume":"42","author":"S Koch","year":"2001","unstructured":"Koch S, Donarski N, Goetze K, et al. Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res. 2001;42(7):1143\u201351.","journal-title":"J Lipid Res"},{"issue":"9","key":"1363_CR38","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/nejmoa2119430","volume":"387","author":"F Conradie","year":"2022","unstructured":"Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022;387(9):810\u201323. https:\/\/doi.org\/10.1056\/nejmoa2119430.","journal-title":"N Engl J Med"},{"issue":"12","key":"1363_CR39","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/psp4.12473","volume":"8","author":"J Lippert","year":"2019","unstructured":"Lippert J, Burghaus R, Edginton A, et al. Open systems pharmacology community\u2014an open access, open source, open science approach to modeling and simulation in pharmaceutical sciences. CPT Pharmacomet Syst Pharmacol. 2019;8(12):878\u201382. https:\/\/doi.org\/10.1002\/psp4.12473.","journal-title":"CPT Pharmacomet Syst Pharmacol."},{"issue":"1","key":"1363_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5588\/ijtld.18.0042","volume":"23","author":"S Perrineau","year":"2019","unstructured":"Perrineau S, Lach\u00e2tre M, L\u00ea MP, Rioux C, Loubet P, Fr\u00e9chet-Jachym M, Gonzales MC, Grall N, Bouvet E, Veziris N, Yazdanpanah Y, Peytavin G. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(1):99\u2013104. https:\/\/doi.org\/10.5588\/ijtld.18.0042.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"1363_CR41","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02399-20","volume":"65","author":"P Ngwalero","year":"2021","unstructured":"Ngwalero P, Brust JCM, van Beek SW, Wasserman S, Maartens G, Meintjes G, Joubert A, Norman J, Castel S, Gandhi NR, Denti P, McIlleron H, Svensson EM, Wiesner L. Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant tuberculosis. Antimicrob Agents Chemother. 2021;65(11): e0239920. https:\/\/doi.org\/10.1128\/AAC.02399-20.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"1363_CR42","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1093\/cid\/ciz1071","volume":"71","author":"EM Svensson","year":"2020","unstructured":"Svensson EM, Dian S, Te Brake L, Ganiem AR, Yunivita V, van Laarhoven A, Van Crevel R, Ruslami R, Aarnoutse RE. Model-based meta-analysis of rifampicin exposure and mortality in indonesian tuberculous meningitis trials. Clin Infect Dis. 2020;71(8):1817\u201323. https:\/\/doi.org\/10.1093\/cid\/ciz1071.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1363_CR43","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000489943","volume":"91","author":"DC Van Essen","year":"2018","unstructured":"Van Essen DC, Donahue CJ, Glasser MF. Development and evolution of cerebral and cerebellar cortex. Brain Behav Evol. 2018;91(3):158\u201369. https:\/\/doi.org\/10.1159\/000489943.","journal-title":"Brain Behav Evol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01363-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01363-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01363-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T17:13:17Z","timestamp":1716225197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01363-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1363"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01363-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"assertion":[{"value":"15 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors provided consent for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data used in the analysis were either obtained from literature (as cited) or were obtained from the TB-PACTS database ().","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Final model codes are provided in the Supplementary Materials.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the study conception and design. The analysis was performed by K.M. The first draft of the manuscript was written by K.M. All authors reviewed and edited the manuscript. All authors reviewed and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}